Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats

Toxicology and Applied Pharmacology

Volumn 194, Issue 1, 2004, Pages 10-23

  Schaefer, William H ^a   Lawrence, Jeffery W ^a   Loughlin, Amy F ^a   Stoffregen, Dana A ^a   Mixson, Lori A ^a   Dean, Dennis C ^a   Raab, Conrad E ^a   Yu, Nathan X ^a   Lankas, George R ^a   Frederick, Clay B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Mitochondria; Myopathy; Statin; Ubiquinone

Indexed keywords

CERIVASTATIN; CREATINE KINASE; UBIQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CIRCULATION; CLINICAL CHEMISTRY; CLINICAL EXAMINATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; DEGENERATION; DIAGNOSTIC PROCEDURE; DISEASE MARKER; DOSE RESPONSE; DRUG MEGADOSE; EVALUATION; EXTENSOR DIGITORUM LONGUS MUSCLE; FEEDING; FEMALE; FUNCTION TEST; HISTOLOGY; HISTOPATHOLOGY; LOW DRUG DOSE; MALE; MITOCHONDRION; MUSCLE FIBRIL; MUSCLE NECROSIS; MYOPATHY; MYOSITIS; NONHUMAN; QUADRICEPS FEMORIS MUSCLE; RAT; SARCOMERE; SOLEUS MUSCLE; STATISTICAL SIGNIFICANCE; TOXICITY; ULTRASTRUCTURE;

ANIMALIA;

EID: 9144239260     PISSN: 0041008X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.taap.2003.08.013     Document Type: Article

References (37)

1. Aberg F., Appelkvist E.L., Dallner G., Ernster L. Distribution and redox state of ubiquinones in rat and human tissues. Arch. Biochem. Biophys. 295:1992;230-234.
2. Alberts A.W. Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol. 62:1988;10J-15J.
3. Alberts A.W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E., Patchett A., Monaghan R., Currie S., Stapley E., Albers-Schonberg G., Hensens O., Hirshfield J., Hoogsteen K., Liesch J., Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. U. S. A. 77:1980;3957-3961.
4. Anonymous Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
5. Baker S.K., Tarnopolsky M.A. Statin myopathies: pathophysiologic and clinical perspectives. Clin. Invest. Med. 24:2001;258-272.
6. Bliznakov E.G., Wilkins D.J. Biochemical and clinical consequences of inhibiting coenzyme Q10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): a critical overview. Adv. Ther. 15:1998;218-228.
7. Capaldi R.A. Arrangement of proteins in the mitochondrial inner membrane. Biochim. Biophys. Acta. 694:1982;291-306.
8. Dallner G., Sindelar P.J. Regulation of ubiquinone metabolism. Free Radical Biol. Med. 29:2000;285-294.
9. Ernster L., Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim. Biophys. Acta. 1271:1995;195-204.
10. Esposti M.D. Assessing functional integrity of mitochondria in vitro and in vivo. Meth. Cell Biol. 65:2001;75-96.
11. Evans M., Rees A. The myotoxicity of statins. Curr. Opin. Lipidol. 13:2002;415-420.
12. Faust J.R., Brown M.S., Goldstein J.L. Synthesis of delta 2-isopentenyl tRNA from mevalonate in cultured human fibroblasts. J. Biol. Chem. 255:1980;6546-6548.
13. Folkers K., Langsjoen P., Willis R., Richardson P., Xia L.J., Ye C.Q., Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc. Natl. Acad. Sci. U. S. A. 87:1990;8931-8934.
14. Ghirlanda G., Oradei A., Manto A., Lippa S., Uccioli L., Caputo S., Greco A.V., Littarru G.P. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J. Clin. Pharmacol. 33:1993;226-229.
15. Grunler J., Ericsson J., Dallner G. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. Biochim. Biophys. Acta. 1212:1994;259-277.
16. Hebert P.R., Gaziano J.M., Chan K.S., Hennekens C.H. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J. Am. Med. Assoc. 278:1997;313-321.
17. Laaksonen R., Jokelainen K., Sahi T., Tikkanen M.J., Himberg J.J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin. Pharmacol. Ther. 57:1995;62-66.
18. Laaksonen R., Jokelainen K., Laakso J., Sahi T., Harkonen M., Tikkanen M.J., Himberg J.J. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am. J. Cardiol. 77:1996;851-854.
19. Lenaz G. A critical appraisal of the mitochondrial coenzyme Q pool. FEBS Lett. 509:2001;151-155.
20. Manfredi G., Spinazzola A., Checcarelli N., Naini A. Assay of mitochondrial ATP synthesis in animal cells. Methods Cell Biol. 65:2001;139-141.
21. Nakahara K., Kuriyama M., Sonoda Y., Yoshidome H., Nakagawa H., Fujiyama J., Higuchi I., Osame M. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol. Appl. Pharmacol. 152:1998;99-106.
22. Naruta Y. Regio- and stereoselective synthesis of coenzymes Qn (n = 2 - 10), vitamin K, and related polyprenylquinones. J. Org. Chem. 45:1980;4097-4104.
23. Okamoto T., Fukui K., Nakamoto M., Kishi T., Okishio T., Yamagami T., Kanamori N., Kishi H., Hiraoka E. High-performance liquid chromatography of coenzyme Q-related compounds and its application to biological materials. J. Chromatogr. 342:1985;35-46.
24. Olson R.E., Rudney H. Biosynthesis of ubiquinone. Vitam. Horm. 40:1983;1-43.
25. Rousseau G., Desrosiers C., Varin F. A comparison of the effects of lovastatin and pravastatin on ubiquinone tissue levels in rats. Curr. Ther. Res. 59:1998;666-679.
26. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333:1995;1301-1307.
27. Shimizu S., Yamamoto T., Sugawara H., Kawahara Y., Momose K. Possible involvement of 3-hydroxymethylglutaryl-CoA reductase in determining the side-chain length of ubiquinone in rat heart. Arch. Biochem. Biophys. 284:1991;35-39.
28. Smith P.F., Eydelloth R.S., Grossman S.J., Stubbs R.J., Schwartz M.S., Germershausen J.I., Vyas K.P., Kari P.H., MacDonald J.S. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J. Pharmacol. Exp. Ther. 257:1991;1225-1235.
29. Srere P.A. Citrate synthase. Methods Enzymol. 13:1969;3-11.
30. Takada M., Ikenoya S., Yuzuriha T., Katayama K. Studies on reduced and oxidized coenzyme Q (ubiquinones): II. The determination of oxidation-reduction levels of coenzyme Q in mitochondria, microsomes and plasma by high-performance liquid chromatography. Biochim. Biophys. Acta. 679:1982;308-314.
31. Thelin A., Schedin S., Dallner G. Half-life of ubiquinone-9 in rat tissues. FEBS Lett. 313:1992;118-120.
32. Thompson P.D., Clarkson P., Karas R.H. Statin-associated myopathy. J. Am. Med. Assoc. 289:2003;1681-1690.
33. von-Keutz E., Schluter G. Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor. Am. J. Cardiol. 82:1998;11J-17J.
34. Waclawik A.J., Lindal S., Engel A.G. Experimental lovastatin myopathy. J. Neuropathol. Exp. Neurol. 52:1993;542-549.
35. Wharton D., Tzagoloff A. Cytochrome oxidase from beef heart mitochondria. Methods Enzymol. 10:1967;245-250.
36. Wicher-Muniak E., Zmudka K., Dabros W., Dudek D., Stachura J. Simvastatin-induced myopathy in a patient treated for hypercholesterolemia. Morphological aspects. Pol. J. Pathol. 48:1997;69-74.
37. Willis R.A., Folkers K., Tucker J.L., Ye C.Q., Xia L.J., Tamagawa H. Lovastatin decreases coenzyme Q levels in rats. Proc. Natl. Acad. Sci. U. S. A. 87:1990;8928-8930.